DE69733966D1 - Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit - Google Patents

Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit

Info

Publication number
DE69733966D1
DE69733966D1 DE69733966T DE69733966T DE69733966D1 DE 69733966 D1 DE69733966 D1 DE 69733966D1 DE 69733966 T DE69733966 T DE 69733966T DE 69733966 T DE69733966 T DE 69733966T DE 69733966 D1 DE69733966 D1 DE 69733966D1
Authority
DE
Germany
Prior art keywords
oral bioavailability
bioverability
lipid compositions
solid lipid
dexanabinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733966T
Other languages
English (en)
Other versions
DE69733966T2 (de
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Application granted granted Critical
Publication of DE69733966D1 publication Critical patent/DE69733966D1/de
Publication of DE69733966T2 publication Critical patent/DE69733966T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
DE69733966T 1996-04-02 1997-04-02 Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit Expired - Fee Related DE69733966T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11777396A IL117773A (en) 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
IL11777396 1996-04-02
PCT/US1997/005453 WO1997036577A1 (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability

Publications (2)

Publication Number Publication Date
DE69733966D1 true DE69733966D1 (de) 2005-09-15
DE69733966T2 DE69733966T2 (de) 2006-05-18

Family

ID=11068733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733966T Expired - Fee Related DE69733966T2 (de) 1996-04-02 1997-04-02 Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit

Country Status (10)

Country Link
US (1) US5989583A (de)
EP (1) EP0954284B1 (de)
JP (1) JP4219403B2 (de)
AT (1) ATE301454T1 (de)
AU (1) AU722217B2 (de)
BR (1) BR9708423A (de)
DE (1) DE69733966T2 (de)
ES (1) ES2249797T3 (de)
IL (1) IL117773A (de)
WO (1) WO1997036577A1 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726343D0 (en) * 1997-12-13 1998-02-11 Auffret Anthony The use of excipients to accelerate freeze-drying
ES2296390T3 (es) * 1998-05-07 2008-04-16 Corixa Corporation Composicion coadyuvante y procedimiento para su uso.
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
DE69939335D1 (de) 1998-12-30 2008-09-25 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6544646B2 (en) 2000-04-27 2003-04-08 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
AU2001279284A1 (en) * 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
DE10035513A1 (de) * 2000-07-21 2002-01-31 Beiersdorf Ag Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
EP1349541B1 (de) * 2000-12-14 2006-10-04 F. Hoffman-la Roche AG Selbstemulgierende lipidmatrix (selm)
EP1343372A2 (de) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonale verabreichung von polyene-antipilzmitteln
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
US6864231B2 (en) * 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
DK1249230T3 (da) * 2001-04-12 2004-03-15 Vesifact Ag Mikroemulsion-prækoncentrater og mikroemulsioner indeholdende coenzym Q10
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US20040015519A1 (en) * 2001-10-15 2004-01-22 Yukitoshi Maeda Content delivery server and content delivery system having the same
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
TW200302054A (en) * 2002-01-18 2003-08-01 Kaneka Corp Ubiquinone-enriched foods
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
AR039194A1 (es) 2002-04-03 2005-02-09 Solvay Pharm Bv Formulacion de cannabinoides naturales estabilizados
EP1492503B1 (de) * 2002-04-03 2008-11-12 Solvay Pharmaceuticals B.V. Stabilisierte natürliche cannabinoid formulierung
US20060093661A1 (en) * 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
JP2006500349A (ja) 2002-08-12 2006-01-05 ファイザー・プロダクツ・インク 半順序薬剤およびポリマーの医薬組成物
PL213863B1 (pl) * 2002-08-19 2013-05-31 Art Jen Complexus Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
CA2414763A1 (en) * 2002-12-19 2004-06-19 Aquanova German Solubilisate Technologies (Agt) Gmbh Tocopherol concentrates and method for producing same
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
JP2004323444A (ja) * 2003-04-25 2004-11-18 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 凍結乾燥微粒子製剤およびその製法
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
CN1946456B (zh) * 2004-02-17 2011-11-09 马库斯·G·V·马图施卡-格雷芬克劳 酒精代谢调节组合物
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
JP4877899B2 (ja) * 2005-01-25 2012-02-15 学校法人近畿大学 薬物徐放出性球状微粒子及びその製造方法
CN101500599A (zh) * 2005-04-14 2009-08-05 杰诺营养保健品公司 用于改善的辅酶q10的递送的营养增补剂制剂及其给予方法
US8252326B2 (en) * 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
WO2007014392A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Benzoquinones of enhanced bioavailability
US10532028B2 (en) 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US8580750B2 (en) 2005-07-29 2013-11-12 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
JP2009521510A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
CA2894933C (en) * 2006-05-02 2017-10-03 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
US20070264312A1 (en) * 2006-05-12 2007-11-15 Skaggs Crawford B Rheologically Modified Edible Oils
CN101472573B (zh) * 2006-06-22 2012-09-19 株式会社钟化 含有还原型辅酶q10的组合物及其制备方法
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2063861B1 (de) 2006-09-15 2015-02-25 Echo Pharmaceuticals B.V. Dosiereinheit zur sublingualen, bukkalen oder oralen verabreichung von wasserunlöslichen pharmazeutischen wirkstoffen
ES2370062T3 (es) * 2006-09-15 2011-12-12 Echo Pharmaceuticals B.V. Granulado que contiene una sustancia farmacéuticamente activa y un emulsionante y método para su producción.
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
EP1952803A1 (de) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Feste pharmazeutische Darreichungsform mit hydrierten Phospholipiden
WO2008092057A2 (en) 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
US20100092560A1 (en) * 2007-04-16 2010-04-15 Kaneka Corporation Reduced coenzyme q10-containing particulate composition and method for producing the same
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
US9861656B2 (en) * 2007-08-08 2018-01-09 Allergy Research Group, Llc Phospholipid compositions and use thereof to enhance spermatozoa motility and viability
FR2929512B1 (fr) * 2008-04-08 2010-12-31 Roquette Freres Composition pulverulente de maltitol cristallise de grande fluidite et non mottante
WO2010022364A1 (en) * 2008-08-22 2010-02-25 Ackley Donald E Water soluble drugs and supplements
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US11224659B2 (en) * 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) * 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9655849B2 (en) 2011-03-18 2017-05-23 Particle Dynamics International, Llc Solid particulate compositions comprising coenzyme Q10
US10421943B2 (en) * 2011-08-11 2019-09-24 Allergy Research Group, Llc Phospholipid compositions and use thereof to enhance spermatozoa motility, viability and resistance to oxydative damage
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
DE102013004263A1 (de) * 2013-03-13 2014-09-18 Martin Lipsdorf Schnell lösliche orale Darreichungsform und Methode zur Herstellung derselben
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
DK3302437T3 (da) * 2015-05-28 2023-01-09 Radius Pharmaceuticals Inc Stabile cannabinoidformuleringer
EP3103440A1 (de) 2015-06-12 2016-12-14 INDENA S.p.A. Feste dispersionen von coenzym q10
WO2017045034A1 (en) * 2015-09-17 2017-03-23 Pharmako Biotechnologies Pty Limited Ubiquinone and ubiquinol compositions, and methods relating thereto
RU2605616C1 (ru) * 2015-11-27 2016-12-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Липосомальное средство на основе убихинола и способ его получения
EP3386480A1 (de) 2015-12-07 2018-10-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zusammensetzungen von therapeutischen stoffen, verfahren und verwendungen davon
CA3176596A1 (en) * 2015-12-09 2017-06-15 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
MA45279A (fr) * 2016-03-02 2019-01-09 Pathway Intermediates Ltd Aliments pour animaux contenant des glycolipides spécifiques
US11166912B2 (en) * 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US20220079881A1 (en) * 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
BE1024442B1 (nl) * 2016-07-27 2018-02-28 Nutrisan Nv Samenstelling en gebruik van een voedingssupplement
US20190183815A1 (en) * 2016-08-15 2019-06-20 Corr-Jensen Inc. TIME RELEASE OF CoQ10
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
JP7173992B2 (ja) 2017-05-17 2022-11-17 バーグ エルエルシー 表皮水疱症の治療および防止におけるコエンザイムｑ１０製剤の使用
CN111148511A (zh) 2017-07-27 2020-05-12 轨迹Ip有限责任公司 用于提高药物、补充剂和摄入物质的生物利用度的组合物
US20210145818A1 (en) * 2018-04-16 2021-05-20 Poviva Tea, Llc Compositions infused with nicotine compounds and methods of use thereof
CN108379236B (zh) * 2018-04-20 2020-02-18 武汉百纳礼康生物制药有限公司 一种非那雄胺缓释片及其制备方法
EP4272731A3 (de) 2018-12-11 2024-02-14 Disruption Labs Inc. Zusammensetzungen zur abgabe von therapeutika und verfahren zu deren verwendung und herstellung
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US20220257772A1 (en) * 2019-07-19 2022-08-18 Spi Pharma, Inc. Preparation of lipophilic active ingredients
EP4009954A4 (de) * 2019-08-10 2023-07-26 Locus IP Company, LLC Verfahren zur erhöhung der bioverfügbarkeit von otc- und pharmazeutischen arzneimitteln
WO2021030702A1 (en) * 2019-08-14 2021-02-18 Locus Ip Company, Llc Drinkable supplement composition for improved health and hydration
US20210330683A1 (en) 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5480865A (en) * 1994-02-25 1996-01-02 Parkinson's Charitable Trust Nutritional composition

Also Published As

Publication number Publication date
EP0954284A4 (de) 2000-01-26
ATE301454T1 (de) 2005-08-15
WO1997036577A1 (en) 1997-10-09
ES2249797T3 (es) 2006-04-01
AU2433997A (en) 1997-10-22
EP0954284A1 (de) 1999-11-10
JP4219403B2 (ja) 2009-02-04
IL117773A0 (en) 1996-08-04
EP0954284B1 (de) 2005-08-10
AU722217B2 (en) 2000-07-27
IL117773A (en) 2000-10-31
DE69733966T2 (de) 2006-05-18
JP2000507594A (ja) 2000-06-20
US5989583A (en) 1999-11-23
BR9708423A (pt) 2000-01-04

Similar Documents

Publication Publication Date Title
ATE301454T1 (de) Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit
JPS5777626A (en) Palatable composition containing oil or oily substance
HUP0302902A2 (hu) A koleszterin-felszívódás csökkentésére alkalmas, emulgeálószer-tartalmú szitosztanol-készítmény
JPS62501908A (ja) 薬理的組成物及びそれを含有する薬理的製剤
ES2191979T3 (es) Sistema de administracion de acido linoleico conjugado en preparaciones cosmeticas.
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
EP0919225A3 (de) Lipidmischung für auf die Lippen
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
CA2264718A1 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
ES2158084T3 (es) Preparaciones vehiculo lipofilicas.
GB9713140D0 (en) Preparation of pharmaceutical compositions
ATE324800T1 (de) Primärzusammensetzung enthaltend einen lipophilen,bioaktiven stoff
NO20004615D0 (no) FremgangsmÕte for fremstilling av linolsyre, og preparater inneholdende denne
HUP0202342A2 (hu) Esszenciális zsírsavakat és homociszteinszint csökkentő hatóanyagokat tartalmazó gyógyászati és élelmiszer-készítmények
AR023338A1 (es) Composicion conteniendo ubiquinona adecuada para promover el transporte mejorado intramitocondrial de ubiquinonas y uso de la misma para preparar unacomposicion alimenticia/farmacologica
MY111841A (en) Injectable liposomal pharmaceutical preparations
WO2002043659A3 (en) Composition containing statins and calcium for improved cardiovascular health
JP2007526303A (ja) 可溶化ｃｏｑ−１０およびカルニチン
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
ES2162586A1 (es) Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
DK0973515T3 (da) Faste sammensætninger, der er egnet til oral indgivelse, hvilke sammensætninger omfatter et alkanoyl-L-carnitinmagnesiumcitrat
CA2462580A1 (en) Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
CA2251194A1 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee